Amphotericin B cas no:1397-89-3

NameAmphotericin B
CAS1397-89-3
SynonymsAmBiosone;Amphotericin .BETA.;Fungizone (TN);Fungizone;Amphozone;Amphotericin B,28,29-dihydro-;Ambisome;[1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E,25E,27E,29E, 31E,33R*,35S*,36R*,37S*)]-33-[(3-Amino-3,6-dideoxy-.beta.-D- mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-;component of Talsutin;component of Mysteclin-F;Ampho-Moronal;Amphotericine B;(1R,3S,5S,8S,9S,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36S,37S)-33-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-oxan-2-yl]oxy-1,3,5,8,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid;Mysteclin-F;(1R,3S,5R,6R,9R,11R,15S,16S,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36S,37S)-33-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-oxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid;33-(4-amino-3,5-dihydroxy-6-methyl-oxan-2-yl)oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid;Lipid nanosphere that incorporates amphotericin B;33-((3-amino-3,6-dideoxyhexopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid;14,39-Dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29, 31-heptaene-36-carboxylic acid, 33-[(3-amino-3, 6-dideoxy-.beta.-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17, 37-octahydroxy-15,16,18-trimethyl-13-oxo-,[1R-(1R*,3S*,5R*,6R*, 9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E,25E,27E,29E,31E,33R*, 35S*,36R*,37S*)]-;Liposomal Amphotericin B;Ribbon form of lipid-stabilized amphotericin B aggregates;Amphocin;Fungisone;Ambisome (TN);IAB;Amphotericin B (JP14/USP);AmB/LIPOSOMAL;(1R,3S,5R,6R,9R,11R,15S,16S,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36S,37S)-33-(4-amino-3,5-dihydroxy-6-methyl-oxan-2-yl)oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid;(1R,3S,5R,6R,9R,11R,15S,16S,17R,18S,33R,35S,36S,37S)-33-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-oxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid;AMPHOTERICIN B, STREPTOMYCES SPECIES;AMPHOMORONAL;NSC-527017;AMPHOTERICIN beta;IODOACETAMIDE;Amphotericin B (U.S. FDA Approved);Amphotericin B (for injection/oral);AmphotericcinB;8055-20-7;
EINECS(EC#)215-742-2
Molecular FormulaC47H73NO17
Molecular Weight924.08

AppearanceCrystalline Yellow Solid
refractive index1.614
storage temp2-8°C

Hazardclass6.1(b)

Hazard Xi:Irritant
Risk R36/37/38
Safety

Hazard Codes: C,Xi,Xn,T
Risk Statements: 36/37/38-22-40-23/24/25 
R36/37/38: Irritating to eyes, respiratory system and skin. 
R22: Harmful if swallowed. 
R40: Limited evidence of a carcinogenic effect. 
R23/24/25: Toxic by inhalation, in contact with skin and if swallowed.
Safety Statements: 26-36/37/39-45 
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. 
S36/37/39: Wear suitable protective clothing, gloves and eye/face protection. 
S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
RIDADR: UN 1759 8/PG 3
WGK Germany: 3
RTECS: BU2625000
F: 8-10-21
HazardClass: 6.1(b)
PackingGroup: III

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	intravenous	6mg/kg (6mg/kg)	KIDNEY, URETER, AND BLADDER: OTHER CHANGES	Biokhimiya Vol. 43, Pg. 2043, 1978.
infant	TDLo	intravenous	15mg/kg/4D-I (15mg/kg)		Journal of Toxicology, Clinical Toxicology. Vol. 28, Pg. 371, 1990.
infant	TDLo	intravenous	15mg/kg/4D-I (15mg/kg)		Journal of Toxicology, Clinical Toxicology. Vol. 28, Pg. 371, 1990.
man	LDLo	intravenous	164ug/kg/5H-I (0.164mg/kg)	CARDIAC: OTHER CHANGES	Drug Intelligence and Clinical Pharmacy. Vol. 17, Pg. 547, 1983.
mouse	LD	unreported	> 50mg/kg (50mg/kg)		Journal of Antibiotics. Vol. 24, Pg. 561, 1971.
mouse	LD12	oral	280mg/kg (280mg/kg)		British UK Patent Application. Vol. #2067993,
mouse	LD50	intramuscular	> 5gm/kg (5000mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 7, Pg. 108, 1976.
mouse	LD50	intraperitoneal	27740ug/kg (27.74mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse	LD50	intravenous	1200ug/kg (1.2mg/kg)		Pharmacy International. Vol. 6, Pg. 164, 1985.
rabbit	LDLo	intravenous	5mg/kg (5mg/kg)	BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Antibiotics Annual. Vol. 5, Pg. 53, 1957/1958.
rat	LD50	intramuscular	> 5gm/kg (5000mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 7, Pg. 108, 1976.
rat	LD50	intraperitoneal	> 5gm/kg (5000mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 7, Pg. 108, 1976.
rat	LD50	intravenous	1600ug/kg (1.6mg/kg)		Journal of Antimicrobial Chemotherapy. Vol. 28(Suppl,
rat	LD50	oral	> 5gm/kg (5000mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 7, Pg. 108, 1976.
women	LDLo	intravenous	22mg/kg/4D-I (22mg/kg)	BLOOD: LEUKOPENIA	Southern Medical Journal. Vol. 76, Pg. 409, 1983.
women	TDLo	intravenous	20ug/kg (0.02mg/kg)	LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	New England Journal of Medicine. Vol. 315, Pg. 836, 1986.
women	TDLo	intravenous	1mg/kg/1H-C (1mg/kg)	CARDIAC: PULSE RATE	Lancet. Vol. 341, Pg. 372, 1993.